Executive Summary
All 8 filings relate to Apollo Hospitals Enterprise, revealing a major strategic pivot during FY2025-26. The company posted solid standalone revenue growth of 13.7% YoY to ₹93,262 Mn and PAT growth of 15.1% YoY, but Q4 FY2026 showed a clear deceleration with sequential revenue growth of only 3.2% and EBITDA flat QoQ, raising concerns about near-term momentum.
The most critical development is the restructuring of its Mother & Child and Fertility verticals via a combination with Cloudnine in a deal valuing those assets at ₹1,550 Cr (subsequently confirmed with an enterprise value of ~₹15,500 Mn for the divested entities), where Apollo will receive cash plus a 9.9% stake in the combined entity. This, along with the merger of Apollo Hospitals North Ltd, signals a balance-sheet optimization strategy. However, a correction filing reveals that the two divested subsidiaries have negative networth (ASHPL: ₹-153.84 Cr, AFCPL: ₹-38.33 Cr), which may indicate a distressed exit. The Digital Health segment continues to bleed cash (₹16 Cr loss in Q4), offsetting strong performance in Healthcare Services (occupancy 68%, ARPIP up 9% YoY). The reappointment of Dr. Prathap C Reddy as Executive Chairman for two more years provides leadership stability. A final dividend of ₹10/share (200%) has been recommended, reflecting continued shareholder returns.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Filing types in this digest: Company update · Board meeting · Corporate action
Tracking the trend? Catch up on the prior India Healthcare Pharma Policy Regulatory Filings digest from May 19, 2026.
Investment Signals (9)
- Apollo Hospitals/Revenue Growth ↓ (BULLISH)▲
Standalone revenue grew 13.7% YoY to ₹93,262 Mn, while PAT grew 15.1% YoY to ₹14,926 Mn, indicating strong underlying business momentum with stable margins
- Apollo Hospitals/Q4 Deceleration ↓ (BEARISH)▲
Q4 FY2026 revenue of ₹24,385 Mn grew only 3.2% QoQ and EBITDA of ₹5,935 Mn was flat vs ₹5,955 Mn in Q3, signaling a clear slowdown in near-term momentum
- Apollo Hospitals/Capital Returns ↓ (BULLISH)▲
Final dividend of ₹10/share (200% of face value ₹5) recommended, with record date Aug 14 and payment by Sep 10, supporting a consistent return policy with 13.7% YoY EPS growth
- Apollo Hospitals/M&A Structure ↓ (BULLISH)▲
Receiving 9.9% equity in the combined entity (Cloudnine + Apollo Cradle/Fertility) aligns Apollo with a high-growth platform backed by Temasek, True North, and TPG NewQuest, creating latent value
- Apollo Hospitals/Divestment Valuation ↓ (BULLISH)▲
Enterprise value of ~₹15,500 Mn for two subsidiaries with combined negative networth of ₹-192.17 Cr suggests Apollo extracted premium valuation, indicating strong deal execution
-
Reappointment of Dr. Prathap C Reddy as Executive Chairman for 2 years from Jun 25, 2026 provides continuity, but also flags succession risk as he remains central at age 92+ [NEUTRAL/BULLISH]
- ▲
Q4 FY26 Healthcare Services segment saw 156,728 in-patients (+7% YoY), ARPIP ₹187,208 (+9% YoY), and occupancy of 68% with established units at 69%, pointing to pricing power and volume growth
- Apollo Hospitals/Digital Health Losses ↓ (BEARISH)▲
Apollo HealthCo posted a cash loss of ₹16 Cr (ex-ESOP) in Q4 FY26, indicating the digital pivot is still burning cash and not yet contributing to profitability
- Apollo Hospitals/Cost Control ↓ (BULLISH)▲
Standalone total expenses grew at a slightly slower pace (12.8% YoY to ₹77,403 Mn) vs revenue growth (13.7%), helping margin expansion
Risk Flags (8)
- Apollo Hospitals/Q4 Slowdown↓ [HIGH RISK]▼
QoQ revenue growth of only 3.2% and flat EBITDA signal that the strong FY2026 run-rate is decelerating entering FY2027, which could disappoint Street expectations
- Apollo Hospitals/Negative Networth Subsidiaries↓ [MODERATE RISK]▼
Filing confirms ASHPL has networth of ₹-153.84 Cr and AFCPL ₹-38.33 Cr; the divestment for ₹15,500 Mn appears to be a rescue sale, suggesting poor capital allocation in these verticals historically
- Apollo Hospitals/Execution Risk in Merger↓ [MODERATE RISK]▼
The combination with Cloudnine (Kids Clinic India) and merger of Apollo Hospitals North Ltd involves complex regulatory approvals including CCI, with integration risk
- Apollo Hospitals/Succession Overhang↓ [MODERATE RISK]▼
Dr. Prathap C Reddy's reappointment for only 2 years at an advanced age raises questions about long-term leadership succession planning
- Apollo Hospitals/Online Pharmacy Losses↓ [MODERATE RISK]▼
Online Pharmacy Distribution segment still reported EBITDA loss of ₹391 Mn in Q4 FY26, although improved from ₹1,253 Mn loss in Q4 FY25; continued cash burn
- Apollo Hospitals/Agenda Item Risk↓ [LOW RISK]▼
Reappointment of Ms. Rama Bijapurkar as Independent Director requires a special resolution, indicating potential shareholder pushback or governance scrutiny
- Apollo Hospitals/Digital Health Sustainability↓ [MODERATE RISK]▼
The Digital Health segment's cash loss (₹16 Cr in Q4) combined with no clear timeline for breakeven poses a drag on consolidated margins
- Apollo Hospitals/Correction Filing↓ [LOW RISK]▼
A correction to the Board Meeting outcome was required, which may raise concerns about disclosure control processes, especially for material subsidiary financials
Opportunities (8)
- Apollo Hospitals/Cloudnine Stake Upside↓ (OPPORTUNITY)◆
Apollo receives a 9.9% stake in the combined entity backed by marquee investors; if the platform scales to 75+ centres and achieves profitability, this stake could be worth significantly more than book value
- Apollo Hospitals/Margins Expansion Potential↓ (OPPORTUNITY)◆
FY26 EBITDA grew 13.9% YoY vs revenue growth 13.7%, with EBITDA margin stable at ~25%; as occupancy improves from 68% toward 75% in established units, operating leverage could boost margins
- Apollo Hospitals/ARPIP Growth Trend↓ (OPPORTUNITY)◆
Average Revenue per In-patient grew 9% YoY to ₹187,208, outpacing medical inflation, indicating Apollo's ability to command premium pricing for tertiary care
- Apollo Hospitals/Q4 Correction Entry↓ (OPPORTUNITY)◆
If the market overreacts to the Q4 slowdown (3.2% QoQ revenue growth) and sells off, it could present a buying opportunity given the strong FY26 underlying growth of 13.7% YoY and 15.1% PAT growth
- Apollo Hospitals/Balance Sheet Simplification↓ (OPPORTUNITY)◆
The merger of Apollo Hospitals North Ltd into the parent will reduce the group structure, potentially improving RoE and simplifying disclosures to the benefit of minority shareholders
- Apollo Hospitals/Dividend Yield Support↓ (OPPORTUNITY)◆
With a final dividend of ₹10/share (200% of face value ₹5), and assuming a ~₹6,000 share price, the yield is ~0.17% - low but consistent; the policy provides a floor for income-focused investors
- Apollo Hospitals/Online Pharmacy Improvement↓ (OPPORTUNITY)◆
The EBITDA loss in Online Pharmacy shrank 69% YoY from ₹1,253 Mn to ₹391 Mn; if this trend continues, the segment could turn positive by FY2028, adding a new profit stream
- Apollo Hospitals/Correction Disclosure Insight↓ (OPPORTUNITY)◆
The correction filing revealing negative networth of divested subsidiaries may have been misread as a negative, but actually shows Apollo sold distressed assets at a premium EV of ₹15,500 Mn, showcasing management's deal-making ability
Sector Themes (5)
- Consolidation in Maternity & Fertility◆
Apollo's combination of its Cradle and Fertility verticals with Cloudnine reflects a broader trend in India's niche healthcare segments, where scale is critical for profitability; expect more M&A in this space driven by PE-backed platforms (Temasek, True North, TPG NewQuest) [IMPLICATION: Sector M&A wave likely]
- Digital Health Still Loss-Making for Incumbents◆
Despite Apollo's strong hospital cash flows, its Digital Health segment (HealthCo) continues to burn cash (₹16 Cr loss in Q4), echoing industry-wide challenges in monetizing health-tech platforms without raising premiums or volumes significantly [IMPLICATION: Monetization timelines for digital health remain extended]
- Occupancy as Core Margin Driver◆
With Apollo reporting 68% overall occupancy and 69% for established units, the industry's path to margin improvement remains tied to occupancy gains; every 1% increase in occupancy can yield significant EBITDA leverage given high fixed cost nature [IMPLICATION: Focus on bed utilization as a key KPI for hospital stocks]
- Premiumisation in Tertiary Care◆
Apollo's 9% YoY ARPIP growth to ₹187,208 far exceeds consumer inflation, suggesting that patients are willing to pay more for advanced procedures; this trend benefits large corporate hospitals with brand equity [IMPLICATION: Apollo, Max, Fortis likely to gain share over smaller players]
- Corporate Restructuring to Unlock Value◆
Apollo is simultaneously divesting assets (Fertility/Mother & Child), merging subsidiaries (North Ltd), and retaining stakes in combined entities (9.9% in Cloudnine entity) – this multi-pronged approach indicates a trend where large hospital chains use SPVs, demergers, and partial exits to optimize capital allocation [IMPLICATION: Watch for similar moves from Fortis, Max, Narayana Health]
Watch List (7)
-
Key items include final dividend approval, reappointment of Dr. Prathap C Reddy as Executive Chairman, reappointment of Ms. Rama Bijapurkar as Independent Director, and shareholder vote on the divestment; any dissent could signal governance friction [Watch for shareholder resolutions outcome]
-
The combination of Apollo Cradle/Fertility with Cloudnine requires Competition Commission of India (CCI) approval; timeline is typically 3-6 months from filing, with closure expected by Q3 FY2027 [Watch for approval or conditions]
-
For final dividend of ₹10/share, ex-date will be around Aug 12, 2026; dividend capture strategies may be relevant for short-term traders [Watch for trading volumes pre-record date]
-
Following the Q4 FY2026 slowdown (+3.2% QoQ revenue), the first quarter of FY2027 (ending Jun 30, 2026) will be crucial to confirm if growth is re-accelerating or if the deceleration is structural [Report expected by mid-Aug 2026]
-
With losses shrinking 69% YoY, investors should monitor monthly run-rate disclosures or management commentary on when the segment can achieve EBITDA breakeven [Watch for guidance in next earnings call]
-
The sale of ASHPL and AFCPL (negative networth) may result in a one-time exceptional gain or loss upon completion; shareholders should watch for the P&L impact in FY2027 disclosed results [Watch for scheme effective date and NCLT approval]
-
With Dr. Prathap C Reddy reappointed only for 2 years, any announcement regarding succession planning or appointment of a Vice Chairman/COO will be closely watched by the market [Watch for any board committee formation on succession]
Filing Analyses
(8)
20-05-2026
Apollo Hospitals Enterprise Limited announced that its subsidiary Apollo Health and Lifestyle Limited (AHLL) is combining its Mother & Child and Fertility verticals (Apollo Cradle and Apollo Fertility) with Kids Clinic India Limited's (Cloudnine) maternity and fertility businesses to create one of India's largest integrated maternity and fertility care platforms. The transaction values AHLL's standalone Mother & Child and Fertility verticals at INR 1,550 Crore, with AHLL receiving a combination of cash and a 9.9% equity stake in the combined entity, making it the largest non-financial shareholder. The combined platform will have 55+ centres and is backed by marquee investors including Temasek, True North, and TPG NewQuest, but the combination is subject to regulatory approvals including CCI.
- · AHLL will have board representation in the combined entity through a nominee director.
- · Cloudnine Founders will continue to hold a minority stake in the combined entity.
- · The combined entity will be driven by a unified professional management team backed by a seasoned board.
- · The combination is subject to regulatory approvals, including from the Competition Commission of India (CCI).
- · Apollo Group operates over 10,400 beds across 76 hospitals, 6,600+ pharmacies, 264 clinics, 2,182 diagnostic centres, and 800+ telemedicine centres.
- · Apollo Group has performed over 3,00,000 angioplasties and 2,00,000 surgeries.
- · Apollo Group employs 1,20,000 family members.
20-05-2026
Apollo Hospitals Enterprise Limited reported standalone revenue from operations of ₹93,262 million for FY2025-26, up 13.7% from ₹82,021 million in the prior year, and profit after tax of ₹14,926 million, up 15.1% from ₹12,963 million. However, the board also approved a transaction to divest its stake in Apollo Specialty Hospitals Private Limited and Apollo Fertility Centre Private Limited to Kids Clinic India Limited at an enterprise value of approximately ₹15,500 million, and approved the merger of wholly owned subsidiary Apollo Hospitals North Ltd into the company. A final dividend of ₹10 per share (200% of face value) was recommended.
- · The board declared that the statutory auditors have issued audit reports with unmodified opinion on the financial statements.
- · The record date for the final dividend and AGM is fixed as August 14, 2026.
- · The dividend, if approved, will be paid on or before September 10, 2026.
- · Dr. Prathap C Reddy was re-appointed as Executive Chairman for two years from June 25, 2026, subject to shareholder approval.
- · Ms. Rama Bijapurkar was re-appointed as Independent Director for a second term of five years from November 12, 2026 to November 11, 2031, subject to shareholder approval by special resolution.
- · The company's credit ratings are AAA (ICRA Ltd) and AA+ (Crisil Ltd).
- · No borrowings were made by way of issuance of debt securities during the year.
- · The standalone balance sheet shows total assets of ₹149,144 million as of March 31, 2026, up from ₹133,723 million a year earlier.
- · Net cash generated from operating activities was ₹20,591 million for FY2025-26, compared to ₹17,419 million in the prior year.
20-05-2026
Apollo Hospitals Enterprise Limited reported standalone revenue from operations of ₹93,262 million for FY2025-26, up 13.7% from ₹82,021 million in FY2024-25, and net profit after tax of ₹14,926 million, up 15.1% from ₹12,963 million. However, Q4 FY2026 revenue of ₹24,385 million was only 3.2% higher than the preceding quarter (₹23,637 million), and EBITDA for the quarter was ₹5,935 million versus ₹5,955 million in Q3 FY2026, indicating a slight sequential decline. The Board recommended a final dividend of ₹10 per share (200% of face value ₹5), approved the re-appointment of Dr. Prathap C Reddy as Executive Chairman for two more years, and approved a transaction to divest stakes in Apollo Specialty Hospitals Private Limited and Apollo Fertility Centre Private Limited to Kids Clinic India Limited for an enterprise value of approximately ₹15,500 million (₹7,650 million cash + 9.9% equity stake).
- · Standalone EBITDA for FY2025-26 was ₹23,280 million, up from ₹20,442 million in FY2024-25 (13.9% YoY growth).
- · Standalone total comprehensive income for FY2025-26 was ₹14,810 million, up from ₹12,965 million in FY2024-25.
- · Standalone basic EPS for FY2025-26 was ₹103.81, compared to ₹90.15 in FY2024-25.
- · Standalone borrowings (non-current + current) increased from ₹17,832.2 million at March 31, 2025 to ₹18,222.2 million at March 31, 2026.
- · The Board approved the merger of wholly owned subsidiary Apollo Hospitals North Ltd into the company via NCLT route.
- · The company's credit ratings: ICRA AAA and Crisil AA+.
- · No debt securities were issued during the year.
- · The AGM is scheduled for August 25, 2026 via video conferencing; record date for dividend and AGM is August 14, 2026; dividend payment on or before September 10, 2026.
20-05-2026
Apollo Hospitals Enterprise reported standalone revenue from operations of ₹93,262 million for FY2025-26, up 13.7% from ₹82,021 million in FY2024-25, and net profit of ₹14,926 million, up 15.1% from ₹12,963 million. However, Q4 FY2026 revenue of ₹24,385 million was only 3.2% higher than the preceding quarter's ₹23,637 million, and EBITDA margin declined sequentially. The Board recommended a final dividend of ₹10 per share (200% of face value ₹5), approved the divestment of Apollo Specialty Hospitals and Apollo Fertility Centre to Kids Clinic India for an enterprise value of ₹15,500 million, and approved the merger of wholly owned subsidiary Apollo Hospitals North Ltd into the company.
- · EBITDA for FY2025-26 was ₹23,280 million, up from ₹20,442 million in FY2024-25.
- · Q4 FY2026 EBITDA was ₹5,935 million, compared to ₹5,955 million in Q3 FY2026 (flat).
- · Total standalone income for FY2025-26 was ₹96,980 million, up from ₹85,498 million.
- · Finance costs for FY2025-26 were ₹2,417 million, down from ₹2,540 million in FY2024-25.
- · The company's credit rating is AAA from ICRA and AA+ from Crisil.
- · Record date for dividend and AGM is August 14, 2026; AGM on August 25, 2026; dividend payment by September 10, 2026.
- · Re-appointment of Dr. Prathap C Reddy as Executive Chairman for two years from June 25, 2026, subject to shareholder approval.
- · Re-appointment of Ms. Rama Bijapurkar as Independent Director for second term from November 12, 2026 to November 11, 2031, subject to special resolution.
- · Merger of Apollo Hospitals North Ltd into the company subject to NCLT and other approvals.
- · No debt securities issued during the year.
20-05-2026
Apollo Hospitals Enterprise Limited reported standalone revenue from operations of ₹93,262 million for FY2025-26, up 13.7% from ₹82,021 million in FY2024-25, and profit after tax of ₹14,926 million, up 15.1% from ₹12,963 million. However, Q4 FY2026 revenue of ₹24,385 million was only 3.2% higher than the preceding quarter's ₹23,637 million, indicating a slowdown. The Board recommended a final dividend of ₹10 per share (200% of face value ₹5) and approved the divestment of subsidiaries Apollo Specialty Hospitals and Apollo Fertility Centre to Kids Clinic India for an enterprise value of ₹15,500 million, as well as the merger of wholly owned subsidiary Apollo Hospitals North Ltd into the company.
- · Standalone EBITDA for FY2025-26 was ₹23,280 million, up from ₹20,442 million in FY2024-25.
- · Standalone total income for FY2025-26 was ₹96,980 million, up from ₹85,498 million.
- · Standalone total expenses for FY2025-26 were ₹77,403 million, up from ₹68,613 million.
- · Standalone finance costs for FY2025-26 were ₹2,417 million, down from ₹2,540 million.
- · Standalone other income for FY2025-26 was ₹3,718 million, up from ₹3,477 million.
- · The Board approved re-appointment of Dr. Prathap C Reddy as Executive Chairman for two years from June 25, 2026.
- · The Board approved re-appointment of Ms. Rama Bijapurkar as Independent Director for a second term of five years from November 12, 2026 to November 11, 2031.
- · Record date for dividend and AGM is August 14, 2026; AGM on August 25, 2026; dividend payment on or before September 10, 2026.
- · Credit rating: AAA by ICRA Ltd and AA+ by Crisil Ltd.
- · No borrowings by way of issuance of debt securities during the year.
20-05-2026
Apollo Hospitals Enterprise Limited reported standalone revenue from operations of ₹93,262 million for FY2026, up 13.7% from ₹82,021 million in FY2025, and profit after tax of ₹14,926 million, up 15.1% from ₹12,963 million. However, Q4 FY2026 revenue of ₹24,385 million grew only 17.5% YoY but EBITDA margin declined sequentially. The Board approved a final dividend of ₹10 per share (200%), the divestment of subsidiaries Apollo Specialty Hospitals and Apollo Fertility Centre to Kids Clinic India for an enterprise value of ₹15,500 million, and the merger of wholly owned subsidiary Apollo Hospitals North Ltd into the company.
- · The Board approved re-appointment of Dr. Prathap C Reddy as Executive Chairman for two years from June 25, 2026, subject to shareholder approval.
- · The Board approved re-appointment of Ms. Rama Bijapurkar as Independent Director for a second term of five years from November 12, 2026 to November 11, 2031, subject to special resolution.
- · Record date for dividend and AGM is August 14, 2026; AGM on August 25, 2026; dividend payment by September 10, 2026.
- · Standalone EBITDA for FY2026 was ₹23,280 million, up 13.9% from ₹20,442 million in FY2025.
- · Outstanding qualified borrowings increased from ₹1,783.23 crore to ₹1,822.22 crore during FY2026.
- · Credit ratings: ICRA AAA and Crisil AA+.
- · The merger of Apollo Hospitals North Ltd into the company is subject to NCLT and other statutory approvals.
20-05-2026
Apollo Hospitals Enterprise Limited reported consolidated revenue of ₹66,055 Mio for Q4 FY26, up 18% YoY, and EBITDA of ₹10,109 Mio (15.3% margin), up 31% YoY. However, the Digital Health segment (Apollo HealthCo) posted a cash loss of ₹16 Cr for the quarter (excluding ESOP charges), and the Online Pharmacy Distribution segment reported an EBITDA loss of ₹391 Mio vs. a loss of ₹1,253 Mio in Q4 FY25. Overall PAT grew 36% YoY to ₹5,292 Mio, but Healthcare Services PAT growth was only 7% due to tax reversals in the prior year.
- · Healthcare Services segment reported 156,728 in-patients in Q4 FY26, up 7% YoY.
- · Average Revenue per In-patient (ARPIP) was ₹187,208, up 9% YoY.
- · Overall occupancy was 68%, with established units at 69%.
- · Apollo 24|7 had 47 Mn+ registered users and ~9 Lacs daily active users.
- · Offline Pharmacy Distribution operated 7,289 stores as of March 31, 2026.
- · Online Pharmacy Distribution EBITDA loss narrowed to ₹391 Mio from ₹1,253 Mio in Q4 FY25.
- · AHLL's Mother & Child and Fertility businesses valued at INR 1,550 Crore in a combination of cash and 9.9% equity stake in the combined entity (subject to CII approval).
- · AHLL operates 316 clinics, 2,501 diagnostics centers, 167 dialysis centers, and 280 dental centers.
- · Consolidated revenue for FY26 was ₹252,285 Mio (up 16% YoY), EBITDA ₹37,693 Mio (up 25% YoY), PAT ₹19,415 Mio (up 34% YoY).
- · Healthcare Services PAT growth of 7% in Q4 FY26 was impacted by tax reversals/adjustments in Q4 FY25.
20-05-2026
Apollo Hospitals Enterprise Limited issued a correction to its earlier Board Meeting outcome disclosure, revising the turnover and networth figures for two subsidiaries: ASHPL and AFCPL. ASHPL reported turnover of ₹351.53 crore and a negative networth of ₹(153.84) crore, while AFCPL reported turnover of ₹100.05 crore and a negative networth of ₹(38.33) crore.
- · The correction pertains to Annexure - 4, SI.No. 1 of the earlier Board Meeting outcome disclosure.
- · Both subsidiaries (ASHPL and AFCPL) have negative networth, indicating liabilities exceed assets.
Get daily alerts with 9 investment signals, 8 risk alerts, 8 opportunities and full AI analysis of all 8 filings
₹500/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: India Healthcare Pharma Policy Regulatory Filings
May 25, 2026
India Healthcare Pharma Policy Regulatory Filings — May 25, 2026
May 16, 2026
India Healthcare Pharma Policy Regulatory Filings — May 16, 2026
May 08, 2026
India Healthcare Pharma Policy Regulatory Filings — May 08, 2026
May 04, 2026
India Healthcare Pharma Policy Regulatory Filings — May 04, 2026
🇮🇳 More from India
View all →May 28, 2026
India Pre-Market Regulatory Roundup — May 28, 2026
India Pre-Market Regulatory Roundup
May 28, 2026
India Quarterly Results BSE NSE Announcements — May 28, 2026
India Quarterly Results BSE NSE Announcements
May 28, 2026
India Upcoming Corporate Actions BSE NSE — May 28, 2026
India Upcoming Corporate Actions BSE NSE
May 27, 2026
India Pre-Market Regulatory Roundup — May 27, 2026
India Pre-Market Regulatory Roundup